Allergology International (Oct 2022)
Executive summary: Japanese pediatric guideline for the treatment and management of asthma (JPGL) 2020
- Yuichi Adachi,
- Takumi Takizawa,
- Masaki Futamura,
- Takao Fujisawa,
- Shigemi Yoshihara,
- Committee members,
- Yuichi Adachi,
- Takumi Takizawa,
- Masaki Futamura,
- Takao Fujisawa,
- Shigemi Yoshihara,
- Naoki Shimojo,
- Akira Iino,
- Mothiro Ebisawa,
- Hiroyuki Mochizuki,
- Yukihiro Ohya,
- Toshio Katsunuma,
- Makoto Kameda,
- Toshishige Inoue,
- Tatsuki Fukuie,
- External committee members,
- Takashi Iwanaga,
- Mariko Kuriyama,
- Haruo Kuroki,
- Mariko Sonobe,
- Masato Takase,
- Ikuyo Masuko,
- Collaborators,
- Fumiya Yamaide,
- Koichi Yoshida,
- Kenichi Nagakura,
- Kota Hirai,
- Yumiko Miyaji,
- Yasunori Ito,
- Hisako Yagi,
- Katsushi Miura,
- Satoshi Horino,
- Hironobu Fukuda,
- Yukinori Yoshida,
- Shinichi Takahashi,
- Osamu Natsume,
- Mizuho Nagao,
- Yoshiyuki Yamada,
- Members of systematic review team,
- Ikuo Okafuji,
- Kiwako Yamamoto-Hanada,
- Yoichi Nakajima,
- Yuya Tanaka,
- Shuichi Suzuki,
- Kotaro Sato,
- Hiroki Murai,
- Taro Miura,
- Yukiko Hiraguchi,
- Yuri Takaoka,
- Tetsuharu Manabe,
- Yu Kuwabara,
- Kenichi Akashi,
- Tomoki Nishikido,
- Mayumi Sugimoto,
- Mayu Maeda,
- Norio Kawamoto,
- Kyohei Takahashi,
- Akiko Yamaide,
- Takuya Wada,
- Hiroshi Kitazawa,
- Mayako Saito,
- Executive Adviser,
- Sankei Nishima
Affiliations
- Yuichi Adachi
- Department of Pediatrics, Faculty of Medicine, University of Toyama, Toyama, Japan; Corresponding author. Department of Pediatrics, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
- Takumi Takizawa
- Department of Pediatrics, Graduate School of Medicine, Gunma University, Maebashi, Japan
- Masaki Futamura
- Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
- Takao Fujisawa
- Department of Pediatrics, National Hospital Organization Mie National Hospital, Tsu, Japan
- Shigemi Yoshihara
- Department of Pediatrics, Dokkyo Medical University, Mibu, Japan
- Committee members
- Yuichi Adachi
- Takumi Takizawa
- Masaki Futamura
- Takao Fujisawa
- Shigemi Yoshihara
- Naoki Shimojo
- Akira Iino
- Mothiro Ebisawa
- Hiroyuki Mochizuki
- Yukihiro Ohya
- Toshio Katsunuma
- Makoto Kameda
- Toshishige Inoue
- Tatsuki Fukuie
- External committee members
- Takashi Iwanaga
- Mariko Kuriyama
- Haruo Kuroki
- Mariko Sonobe
- Masato Takase
- Ikuyo Masuko
- Collaborators
- Fumiya Yamaide
- Koichi Yoshida
- Kenichi Nagakura
- Kota Hirai
- Yumiko Miyaji
- Yasunori Ito
- Hisako Yagi
- Katsushi Miura
- Satoshi Horino
- Hironobu Fukuda
- Yukinori Yoshida
- Shinichi Takahashi
- Osamu Natsume
- Mizuho Nagao
- Yoshiyuki Yamada
- Members of systematic review team
- Ikuo Okafuji
- Kiwako Yamamoto-Hanada
- Yoichi Nakajima
- Yuya Tanaka
- Shuichi Suzuki
- Kotaro Sato
- Hiroki Murai
- Taro Miura
- Yukiko Hiraguchi
- Yuri Takaoka
- Tetsuharu Manabe
- Yu Kuwabara
- Kenichi Akashi
- Tomoki Nishikido
- Mayumi Sugimoto
- Mayu Maeda
- Norio Kawamoto
- Kyohei Takahashi
- Akiko Yamaide
- Takuya Wada
- Hiroshi Kitazawa
- Mayako Saito
- Executive Adviser
- Sankei Nishima
- Journal volume & issue
-
Vol. 71,
no. 4
pp. 472 – 480
Abstract
This article covers the salient and updated themes of the Japanese Pediatric Guidelines for the Treatment and Management of Asthma (JPGL) 2020 published by the Japanese Society of Pediatric Allergy and Clinical Immunology. In the 2020 guidelines, five new clinical questions (CQs) have been added to address the 12 CQs regarding the treatment of childhood asthma. “Infant and preschool asthma” is diagnosed when young children (<6 years of age) have three or more episodes of clear expiratory wheezing, which continue for more than 24 h, and symptom improvement can be observed after beta-2 agonist inhalation. In children without clear improvement, diagnostic therapeutic trial for the duration of 1 month with controller treatment can be used. Since long-term management is initiated, the treatment level is adjusted based on the current control status and the management of risk factors, with the provision for holistic care. This underscores the smooth transition of pediatric patients into adult services. There are several differences between the JPGL and the guidelines of other countries. Further evidence is obtained as the utility of the newly proposed management plans should be evaluated in the Japanese population.
